This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.

Trial Details

NCT ID

NCT07249879

Phase

PHASE1

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

GC511B CAR-T Cell Injection

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723
Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Trial articipant must be ≥ 18 years and ≤75 years of age at the time of signing the ICF.
Type of Subjects and Disease Characteristics
ECOG performance status 0-2.
Life expectancy ≥ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →